Advanced Science | CTSB+ Glioblastoma Cells and S100A10+ Macrophages Interact to Promote Immune Evasion and Limit Immunotherapy Response

This study reveals the critical interaction mechanism between CTSB and S100A10 in glioblastoma, providing a direct theoretical basis and target selection strategy for designing experimental protocols combining immune checkpoint blockade therapies.

 

Literature Overview

This article, titled "Crosstalk Between CTSB+ Glioblastoma Cells and S100A10+ Macrophages: A Self-Reinforcing Circuit Promotes Immune Evasion and Limits Response to Immunotherapy," published in Advanced Science, systematically explores the self-reinforcing signaling circuit formed by CTSB and S100A10 between tumor cells and tumor-associated macrophages (TAMs) in glioblastoma (GBM). This mechanism is a core factor driving the immunosuppressive tumor microenvironment and resistance to immunotherapy.

Background Knowledge

1. The key challenge addressed by this research in glioblastoma is its extremely high recurrence rate and poor prognosis. Despite advances in surgery, radiotherapy, and chemotherapy, the median survival of patients remains less than 15 months, with the core obstacle being its highly immunosuppressive tumor microenvironment.
2. The current bottleneck in CTSB research lies in the unclear specific intercellular communication mechanisms mediated by CTSB in GBM, particularly how it interacts with immune cells to maintain a malignant ecosystem.
3. The entry point for this study involves utilizing multi-omics network analysis and artificial intelligence technologies to screen for CTSB genes highly correlated with TAMs, and to deeply analyze its molecular mechanisms of regulation via the IL-6/STAT3 axis and binding with the S100A10 protein, thereby identifying new targets to reverse immunosuppression.

 

 

Research Methods and Core Experiments

The authors integrated bio-network analysis and machine learning algorithms on large-scale clinical cohorts (TCGA, CGGA, GEO) to screen CTSB as a key target. At the experimental validation level, a co-culture system of glioblastoma and macrophages was constructed. Using techniques such as Chromatin Immunoprecipitation (ChIP), dual-luciferase reporter assays, molecular docking, and Co-Immunoprecipitation (Co-IP), the transcriptional activation of CTSB by STAT3 and the binding mechanism between CTSB and S100A10 were elucidated at the molecular level.

In the in vivo validation phase, the study employed orthotopic (GL261 and CT-2A) and subcutaneous xenograft models of glioblastoma. Lentivirus-mediated CTSB knockdown combined with anti-PD-1 therapy was used to evaluate tumor growth, immune cell infiltration, and survival changes. Furthermore, single-cell RNA sequencing (scRNA-seq) and multiplex immunofluorescence (mIF) technologies were utilized to dynamically monitor changes in the cellular atlas of the tumor microenvironment following intervention, particularly the spatial distribution and phenotypic transformation of CD8+ T cells and TAMs.

Key Conclusions and Perspectives

• Macrophage-derived IL-6 activates the STAT3 signaling pathway within tumor cells, transcriptionally upregulating CTSB expression, confirming that the IL-6/STAT3/CTSB axis is a key mechanism driving malignant tumor progression.
• CTSB protein secreted by tumor cells specifically binds to the C-terminus of S100A10 on the macrophage surface, forming a positive feedback loop that further promotes IL-6 secretion, thereby reinforcing the immunosuppressive microenvironment.
• Clinical samples show significant spatial co-localization between CTSB+ tumor cells and S100A10+ TAMs, and high CTSB expression is closely associated with poor patient prognosis and low immune cell infiltration.
• In glioblastoma mouse models, CTSB knockdown not only reduces TAM activity and PD-L1 expression but also significantly increases CD8+ T cell infiltration, producing a synergistic anti-tumor effect when combined with anti-PD-1 therapy.

Research Significance and Prospects

This discovery provides a new combination therapy strategy for drug development: targeting CTSB can remodel the immune microenvironment and overcome resistance to immune checkpoint blockade therapies in glioblastoma.
In terms of clinical monitoring, CTSB and S100A10 can serve as potential biomarkers for predicting immunotherapy response and assessing prognosis.
For disease modeling, the glioblastoma-macrophage interaction model and key molecular axis established in this study provide a standardized experimental platform for screening inhibitors targeting this pathway.

 

 

Conclusion

This study deeply analyzes the molecular foundation of immune evasion in glioblastoma, revealing that the self-reinforcing circuit formed by CTSB and S100A10 is key to maintaining the immunosuppressive state of the tumor microenvironment. From laboratory mechanism elucidation to clinical translation, this finding not only explains why single-agent immunotherapy has limited efficacy in glioblastoma but also provides conclusive evidence for developing combination targeting strategies. By blocking the interaction between CTSB and S100A10, it is hoped that the vicious cycle can be broken, restoring the cytotoxic function of CD8+ T cells, thereby significantly enhancing the efficacy of immune checkpoint blockade therapies. This achievement lays a solid scientific foundation for future precision medicine and the formulation of comprehensive treatment strategies for glioblastoma, marking an important shift from simple cell killing to microenvironment remodeling treatment strategies.

 

Hao Zhang, Nan Zhang, Xisong Liang, Peng Luo, and Quan Cheng. Crosstalk Between CTSB+ Glioblastoma Cells and S100A10+ Macrophages: A Self‐Reinforcing Circuit Promotes Immune Evasion and Limits Response to Immunotherapy. Advanced Science.